Statins and breast cancer in postmenopausal women without hormone therapy

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5143-5148

  Eaton, Mark ^a   Eklof, Jonathan ^a   Beal, James R ^a   Sahmoun, Abe Eric ^b  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

Breast cancer; Epidemiology; Obese; Overweight; Postmenopausal women; Statins

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DRUG USE; FEMALE; HORMONAL THERAPY; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR VOLUME; UNITED STATES;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 75149127674     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E et al: Cancer Statistics. CA Cancer J Clin 59: 228, 2009.
2. American Cancer Society. Breast Cancer Facts and Figures 2005-2006. Atlanta: American Cancer Society, Inc. pp. 1-23, 2005.
3. Morimoto LM, White E, Chen Z et al: Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 13: 741-751, 2002.
4. Borgquist S, Djerbi S, Ponten F et al: HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer 123: 1146-1153, 2008.
5. Huang Z, Hankinson SE, Colditz GA et al: Dual effects of weight and weight gain on breast cancer risk. JAMA 278: 1407-1411, 1997.
6. Lennernas H and Fager G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32: 403-425, 1997.
7. Cauley JA, McTiernan A, Rodabough RJ et al: Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 98: 700-707, 2006.
8. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK and Dating JR: The association between 3-hydroxy-3 methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100: 2308-2316, 2004.
9. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR and Daling JR: Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 16: 416-421, 2007.
10. Eliassen AH, Colditz GA, Rosner B, Willett WC and Hankinson SE: Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 165: 2264-2271, 2005.
11. Beck P, Wysowski DK, Downey W and Butler-Jones D: Statin use and the risk of breast cancer. J Clin Epidemiol 56: 280-285, 2003.
12. Kaye JA, Meier CR, Walker AM and Jick H: Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer 86: 1436-1439, 2002.
13. Blais L, Desgagne A and LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160: 2363-2368, 2000.
14. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG and Shapiro S: Statin use and the risk of breast and prostate cancer. Epidemiology 13: 262-267, 2002. 15 Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ and Guchelaar HJ: The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394, 2004.
15. Friis S, Poulsen AH, Johnsen SP et al: Cancer risk among statin users: a population-based cohort study. Int J Cancer 114: 643-647, 2005.
16. http://en.wikipedia.org/wiki/North-Dakota (Accessed on 9/30/2009).
17. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R and Bernini F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84: 413-428, 1999.
18. Prowell TM, Stearns V and Trock B: Lipophilic statins merit additional study for breast cancer chemoprevention. J Clin Oncol 24: 2128-2129, 2006.
19. Sprague JR and Wood ME: Statins and breast cancer prevention: time for randomized controlled trials. J Clin Oncol 24: 2129-2130, 2006.
20. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E et al: Breast cancer growth prevention by statins. Cancer Res 66(17): 8707-8714, 2006.
21. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17: 2393-2402, 1998.
22. Cauley JA, Zmuda JM, Lui LY et al: Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12(8): 749-756, 2003.
23. Campbell MJ, Esserman LJ, Zhou Y et al: Breast cancer growth prevention by statins. Cancer Res 66: 8707-8714, 2006.
24. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH and Esserman LJ: Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 17(5): 1028-1033, 2008.
25. Suzuki R, Rylander-Rudqvist T, Ye W, Saji S and Wolk A: Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study. Int J Cancer 119(7): 1683-1689, 2006.
26. Suzuki R, Orsini N, Saji S, Key TJ and Wolk A: Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer 124(3): 698-712, 2009.
27. Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G et al: Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 162: 404-414, 2005.